264 related articles for article (PubMed ID: 10715303)
1. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
[TBL] [Abstract][Full Text] [Related]
2. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
[TBL] [Abstract][Full Text] [Related]
3. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
Davies AJ; Rohatiner AZ; Howell S; Britton KE; Owens SE; Micallef IN; Deakin DP; Carrington BM; Lawrance JA; Vinnicombe S; Mather SJ; Clayton J; Foley R; Jan H; Kroll S; Harris M; Amess J; Norton AJ; Lister TA; Radford JA
J Clin Oncol; 2004 Apr; 22(8):1469-79. PubMed ID: 15084620
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
[TBL] [Abstract][Full Text] [Related]
5. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD
Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
[TBL] [Abstract][Full Text] [Related]
6. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
[TBL] [Abstract][Full Text] [Related]
7. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
[TBL] [Abstract][Full Text] [Related]
8. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
[TBL] [Abstract][Full Text] [Related]
9. The radioisotope contributes significantly to the activity of radioimmunotherapy.
Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
Kaminski MS; Estes J; Zasadny KR; Francis IR; Ross CW; Tuck M; Regan D; Fisher S; Gutierrez J; Kroll S; Stagg R; Tidmarsh G; Wahl RL
Blood; 2000 Aug; 96(4):1259-66. PubMed ID: 10942366
[TBL] [Abstract][Full Text] [Related]
11. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Friedberg JW; Fisher RI
Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
16. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
Wahl RL
J Nucl Med; 2005 Jan; 46 Suppl 1():128S-40S. PubMed ID: 15653661
[TBL] [Abstract][Full Text] [Related]
17. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
[TBL] [Abstract][Full Text] [Related]
20. Development of 131I-tositumomab.
Lewington V
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]